...
首页> 外文期刊>Open Forum Infectious Diseases >Activation of Latent Human Immunodeficiency Virus by the Histone Deacetylase Inhibitor Panobinostat: A Pilot Study to Assess Effects on the Central Nervous System
【24h】

Activation of Latent Human Immunodeficiency Virus by the Histone Deacetylase Inhibitor Panobinostat: A Pilot Study to Assess Effects on the Central Nervous System

机译:组蛋白脱乙酰基酶抑制剂Panobinostat激活潜在的人类免疫缺陷病毒:评估对中枢神经系统影响的一项初步研究。

获取原文
           

摘要

In a substudy of a clinical trial, we assessed whether activation of latent human immunodeficiency virus (HIV) by the histone deacetylase inhibitor panobinostat had detrimental effects on the central nervous system (CNS). Adults infected with HIV received oral panobinostat 20 mg 3 times per week every other week for 8 weeks. In cerebrospinal fluid (CSF), we assayed panobinostat concentration, HIV RNA, and the level of neuroinflammatory or degenerative biomarkers in 11 individuals before and during study therapy. Neither panobinostat nor HIV RNA was detected in CSF. In addition, there was no change from baseline in CSF biomarkers. Thus, panobinostat administration was not associated with CNS adverse effects as assessed by CSF biomarkers.
机译:在一项临床试验的子研究中,我们评估了组蛋白脱乙酰基酶抑制剂panobinostat激活潜在的人类免疫缺陷病毒(HIV)是否对中枢神经系统(CNS)有有害影响。感染了HIV的成人每周8次,每周两次口服panobinostat 20 mg,共8周。在脑脊液(CSF)中,我们在研究治疗之前和研究期间对11名患者的panobinostat浓度,HIV RNA和神经炎性或变性生物标志物水平进行了测定。脑脊液中未检出pa​​nobinostat或HIV RNA。另外,CSF生物标志物与基线相比没有变化。因此,如通过CSF生物标志物评估的那样,panobinostat给药与CNS不良反应无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号